BXRX
Baudax Bio, Inc. [BXRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BXRX Stock Summary
In the News
BXRX Financial details
Company Rating
Neutral
Market Cap
950.33K
Income
-7.15M
Revenue
326K
Book val./share
-1.28
Cash/share
0.05
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.04
Forward P/E
-
PEG
0
P/S
4.32
P/B
-0.03
P/C
0.44
P/FCF
-0.1
Quick Ratio
0.02
Current Ratio
0.07
Debt / Equity
-0.79
LT Debt / Equity
-0.25
-
-
EPS (TTM)
-2.54
EPS next Y
-
EPS next Q
-
EPS this Y
-50.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-84.11%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.01%
Inst Trans
0%
ROA
-35%
ROE
55%
ROC
-14.43%
Gross Margin
-1539%
Oper. Margin
-6782%
Profit Margin
-2194%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0137-3.4699
52W High
-
52W Low
-
RSI
49
Rel Volume
0.73
Avg Volume
424.85K
Volume
310.87K
Perf Week
30.54%
Perf Month
-22.14%
Perf Quarter
-
Perf Half Y
-89.1%
-
-
-
-
Beta
1.583
-
-
Volatility
0%, 0%
Prev Close
28.24%
Price
0.0218
Change
50.34%
BXRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 37.03 | 19.73 | 3.83 | |
| Net income per share | -11.36K | -2.7K | -5.72K | -361.16 | -177.3 | |
| Operating cash flow per share | -9.22K | -7.49K | -3.31K | -900.11 | -83.81 | |
| Free cash flow per share | -9.75K | -7.72K | -3.36K | -903.81 | -83.87 | |
| Cash per share | 0 | 2.66K | 2.28K | 290.31 | 15.86 | |
| Book value per share | -10.54K | -2.5K | -1.11K | 241.62 | -73.1 | |
| Tangible book value per share | -14.94K | -6.78K | -3.09K | -193.27 | -79.52 | |
| Share holders equity per share | -10.54K | -2.5K | -1.11K | 241.62 | -73.1 | |
| Interest debt per share | 0 | 115.75 | 836.43 | 197.92 | 85.01 | |
| Market cap | 63.54M | 64.7M | 18.83M | 16.78M | 1.05M | |
| Enterprise value | 63.54M | 47.73M | -1.74M | 9.42M | 2.91M | |
| P/E ratio | -0.86 | -3.59 | -0.25 | -0.85 | -0.02 | |
| Price to sales ratio | 0 | 0 | 38.19 | 15.54 | 0.83 | |
| POCF ratio | -1.06 | -1.29 | -0.43 | -0.34 | -0.04 | |
| PFCF ratio | -1.01 | -1.26 | -0.42 | -0.34 | -0.04 | |
| P/B Ratio | -0.93 | -3.87 | -1.27 | 1.27 | -0.04 | |
| PTB ratio | -0.93 | -3.87 | -1.27 | 1.27 | -0.04 | |
| EV to sales | 0 | 0 | -3.52 | 8.72 | 2.3 | |
| Enterprise value over EBITDA | -1.13 | -0.78 | 0.03 | -0.2 | -0.23 | |
| EV to operating cash flow | -1.06 | -0.95 | 0.04 | -0.19 | -0.1 | |
| EV to free cash flow | -1.01 | -0.93 | 0.04 | -0.19 | -0.1 | |
| Earnings yield | -1.16 | -0.28 | -4.04 | -1.18 | -55.75 | |
| Free cash flow yield | -0.99 | -0.8 | -2.37 | -2.95 | -26.37 | |
| Debt to equity | 0 | -0.05 | -0.66 | 0.65 | -0.29 | |
| Debt to assets | 0 | 0.01 | 0.14 | 0.16 | 0.71 | |
| Net debt to EBITDA | 0 | 0.28 | 0.39 | 0.15 | -0.15 | |
| Current ratio | 0.11 | 2.61 | 2.03 | 1.5 | 0.3 | |
| Interest coverage | 0 | 0 | -55.03 | -8.25 | -2.7 | |
| Income quality | 0.81 | 1.54 | 0.58 | 2.49 | 0.47 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 11.59 | |
| Research and developement to revenue | 0 | 0 | 18.43 | 2.89 | 3.06 | |
| Intangibles to total assets | 0.81 | 0.53 | 0.38 | 0.45 | 0.21 | |
| Capex to operating cash flow | 0.06 | 0.03 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -1.3 | -0.19 | -0.02 | |
| Capex to depreciation | -8.72 | -3.09 | -0.25 | -0.07 | -0.01 | |
| Stock based compensation to revenue | 0 | 0 | 18.95 | 4.43 | 1.1 | |
| Graham number | 51.91K | 12.32K | 11.96K | 1.4K | 540.02 | |
| ROIC | 1.07 | 1.18 | 17.33 | -1.04 | 4.62 | |
| Return on tangible assets | -11.34 | -0.7 | -1.8 | -0.67 | -7.44 | |
| Graham Net | -15.94K | -7.97K | -3.88K | -388.26 | -86.74 | |
| Working capital | -20.27M | 12.42M | 18.59M | 7.85M | -15.11M | |
| Tangible asset value | -96.87M | -45.25M | -41.18M | -10.58M | -26.37M | |
| Net current asset value | -100.86M | -50.8M | -46.82M | -16.56M | -27.93M | |
| Invested capital | 0 | -0.05 | -0.66 | 0.65 | -0.29 | |
| Average receivables | 0 | 0 | 25.5K | 296.5K | 438.5K | |
| Average payables | 4.9M | 1.46M | 1.96M | 2.56M | 2.7M | |
| Average inventory | 0 | 0 | 1.49M | 3.99M | 2.5M | |
| Days sales outstanding | 0 | 0 | 37.76 | 183.18 | 96.36 | |
| Days payables outstanding | 0 | 0 | 769.83 | 219.15 | 204.5 | |
| Days of inventory on hand | 0 | 0 | 627.58 | 746.72 | 0 | |
| Receivables turnover | 0 | 0 | 9.67 | 1.99 | 3.79 | |
| Payables turnover | 0 | 0 | 0.47 | 1.67 | 1.78 | |
| Inventory turnover | 0 | 0 | 0.58 | 0.49 | 0 | |
| ROE | 1.08 | 1.08 | 5.14 | -1.49 | 2.43 | |
| Capex per share | -532.39 | -222.22 | -47.99 | -3.71 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.8 | 0.19 | -0.01 | 0.01 | 0 | |
| Net income per share | -98.7 | -5.7 | 4.91 | -1.51 | -0.24 | |
| Operating cash flow per share | -13.14 | -2.33 | -2.01 | -0.71 | -0.3 | |
| Free cash flow per share | -13.21 | -2.3 | -2.01 | -0.71 | -0.3 | |
| Cash per share | 19.08 | 3.24 | 1.64 | 0.29 | 0.05 | |
| Book value per share | -66.04 | -14.93 | -3.15 | -2.19 | -1.28 | |
| Tangible book value per share | -79.98 | -16.24 | -4.06 | -4.79 | -2.87 | |
| Share holders equity per share | -66.04 | -14.93 | -3.15 | -2.19 | -1.28 | |
| Interest debt per share | 180.28 | 4.95 | -3.82 | 1.8 | 1.01 | |
| Market cap | 2.91M | 5.16M | 3.95M | 5.72M | 2.96M | |
| Enterprise value | 5.35M | 7.02M | 7.58M | 13.07M | 10.69M | |
| P/E ratio | -0.02 | -0.14 | 0.09 | -0.19 | -0.38 | |
| Price to sales ratio | 12.23 | 16.66 | -282.03 | 190.52 | 0 | |
| POCF ratio | -0.75 | -1.37 | -0.85 | -1.66 | -1.23 | |
| PFCF ratio | -0.75 | -1.38 | -0.85 | -1.66 | -1.23 | |
| P/B Ratio | -0.15 | -0.21 | -0.54 | -0.54 | -0.29 | |
| PTB ratio | -0.15 | -0.21 | -0.54 | -0.54 | -0.29 | |
| EV to sales | 22.48 | 22.66 | -541.32 | 435.69 | 0 | |
| Enterprise value over EBITDA | 0.31 | -1.05 | -1.62 | -12.81 | -6.02 | |
| EV to operating cash flow | -1.38 | -1.86 | -1.62 | -3.79 | -4.43 | |
| EV to free cash flow | -1.37 | -1.88 | -1.62 | -3.79 | -4.43 | |
| Earnings yield | -10.03 | -1.79 | 2.89 | -1.29 | -0.65 | |
| Free cash flow yield | -1.34 | -0.72 | -1.18 | -0.6 | -0.82 | |
| Debt to equity | -0.41 | -0.29 | -1.02 | -0.82 | -0.79 | |
| Debt to assets | 0.46 | 0.71 | 1.05 | 0.41 | 0.39 | |
| Net debt to EBITDA | 0.14 | -0.28 | -0.77 | -7.21 | -4.35 | |
| Current ratio | 0.53 | 0.3 | 0.33 | 0.09 | 0.07 | |
| Interest coverage | 0.37 | -9.34 | 0.29 | 0 | 0 | |
| Income quality | 0.13 | 0.41 | 0.63 | 0.47 | 1.28 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 75.13 | 0 | |
| Research and developement to revenue | 2.71 | 3.35 | -208.36 | 59.3 | 0 | |
| Intangibles to total assets | 0.24 | 0.21 | 0.3 | 0.6 | 0.62 | |
| Capex to operating cash flow | 0.01 | -0.01 | 0 | 0 | 0 | |
| Capex to revenue | -0.08 | 0.13 | 0 | 0 | 0 | |
| Capex to depreciation | -0.03 | 0.38 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 1.32 | 0.74 | -13.64 | 6.6 | 0 | |
| Graham number | 382.94 | 43.74 | 18.65 | 8.62 | 2.64 | |
| ROIC | -1.47 | 0.59 | -40.16 | -10 | -7.49 | |
| Return on tangible assets | -2.18 | -1.17 | 2.31 | -0.86 | -0.25 | |
| Graham Net | -97.77 | -17.71 | -4.55 | -6.26 | -3.81 | |
| Working capital | -10.01M | -15.11M | -8.26M | -18.6M | -17.71M | |
| Tangible asset value | -23.67M | -26.37M | -9.44M | -23.42M | -22.94M | |
| Net current asset value | -25.78M | -27.93M | -10.27M | -30.14M | -29.48M | |
| Invested capital | -0.41 | -0.29 | -1.02 | -0.82 | -0.79 | |
| Average receivables | 464.5K | 324K | 167.5K | 0 | 0 | |
| Average payables | 3.34M | 3.77M | 3.88M | 4.83M | 6.83M | |
| Average inventory | 4.87M | 2.24M | 0 | 0 | 0 | |
| Days sales outstanding | 118.36 | 97.26 | 0 | 0 | 0 | |
| Days payables outstanding | 268.88 | 73.75 | 852.67 | 5.04K | 16.37K | |
| Days of inventory on hand | 333.55 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.76 | 0.93 | 0 | 0 | 0 | |
| Payables turnover | 0.33 | 1.22 | 0.11 | 0.02 | 0.01 | |
| Inventory turnover | 0.27 | 0 | 0 | 0 | 0 | |
| ROE | 1.49 | 0.38 | -1.56 | 0.69 | 0.19 | |
| Capex per share | -0.07 | 0.02 | 0 | 0 | 0 |
BXRX Frequently Asked Questions
What is Baudax Bio, Inc. stock symbol ?
Baudax Bio, Inc. is a US stock , located in Malvern of Pa and trading under the symbol BXRX
What is Baudax Bio, Inc. stock quote today ?
Baudax Bio, Inc. stock price is $0.0218 today.
Is Baudax Bio, Inc. stock public?
Yes, Baudax Bio, Inc. is a publicly traded company.
Company Profile
- Volume Average 424.85K
- Market Capitalization 950.33K
- Employee 9
- CEO Dr. Geraldine A. Henwood Ph.D.
- Headquarters Malvern,PA,US
- IPO Date 2019-11-14
-
Website
https://www.baudaxbio.com 
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
